BLTE
Belite Bio Makes Groundbreaking Progress in Q1 2026: Initiating NDA Rolling Submission and Preparing for Commercial Launch
Belite Bio, a leading biotechnology company focused on developing innovative treatments for retinal degenerative diseases, has made significant progress in the first quarter of 2026. During its recent earnings call, the company announced that it has received its phase III clinical study report and initiated its NDA rolling submission to